Product Information
KATERZIA 1 MG/ML SUSPENSION is a brand product labeled by Azurity Pharmaceuticals Inc., priced at $4.2032 per ML under NDC 52652500101. Its NADAC has been published 337 times since Apr 22, 2020.
FDA first approved this application on Jul 8, 2019.
Strength
1 mg/mL
Manufacturer
Azurity Pharmaceuticals Inc.NDC
52652500101
Classification
Brand
Dosage Form
SUSPENSION
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
AMLODIPINE BENZOATEApproval Type
New Drug (NDA)
FDA Application
NDA211340FDA Approved
7/8/2019
On Market Since
8/15/2019
Pharmacological Classes
Price Statistics
The NADAC for KATERZIA 1 MG/ML SUSPENSION has been published 337 times since Apr 22, 2020, and over the history we have for it it has risen 33.2%. The table below summarizes its recorded NADAC range and movement.
| Current price | $4.2032 per ML |
|---|---|
| All-time high | $4.2151 (Jun 10, 2026) |
| All-time low | $3.1564 (Apr 22, 2020) |
| 52-week high | $4.2151 |
| 52-week low | $4.0674 |
| Median price | $3.5311 |
| Average price | $3.6346 |
| Largest weekly change | +9.0% (Jan 15, 2025) |
| Weeks tracked | 337 |
| Tracking since | Apr 22, 2020 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Amlodipine market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Azurity Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Amlodipine market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Calcium Channel Blocker class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of KATERZIA 1 MG/ML SUSPENSION?
The current National Average Drug Acquisition Cost (NADAC) for KATERZIA 1 MG/ML SUSPENSION, manufactured by Azurity Pharmaceuticals Inc., is $4.2032 per ML (NDC 52652500101), effective Sep 30, 2026.
How has the price of KATERZIA 1 MG/ML SUSPENSION changed over time?
Over the history we have for it, the NADAC for KATERZIA 1 MG/ML SUSPENSION has risen 33.2%. It has been tracked across 337 weekly CMS publications since Apr 22, 2020.
What are the highest and lowest recorded NADAC prices for KATERZIA 1 MG/ML SUSPENSION?
Since Apr 22, 2020, the NADAC for KATERZIA 1 MG/ML SUSPENSION has ranged from a low of $3.1564 (Apr 22, 2020) to a high of $4.2151 (Jun 10, 2026), with a median of $3.5311 per ML.
Are there cheaper alternatives to KATERZIA 1 MG/ML SUSPENSION?
No other NADAC-published product currently shares the active ingredient and strength of KATERZIA 1 MG/ML SUSPENSION in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures KATERZIA 1 MG/ML SUSPENSION?
KATERZIA 1 MG/ML SUSPENSION (NDC 52652500101) is labeled by Azurity Pharmaceuticals Inc., and CMS classifies it as a brand product.